The case of double primary lung adenocarcinomas with an EGFR mutation and ALK translocation successfully treated with alectinib at the post-surgical recurrence

Yoshio Tsunezuka; Nobuyoshi Tanaka; Hideki Fujimori; Yuki Togashi; Satoko Baba; Kengo Takeuchi; Kazuyoshi Katayanagi; Hiroshi Kurumaya; Hironori Kitade; Shinji Atagi; Seiji Yano

doi:10.2152/jmi.64.305

Case reports

The case of double primary lung adenocarcinomas with an EGFR mutation and ALK translocation successfully treated with alectinib at the post-surgical recurrence

Yoshio Tsunezuka, Nobuyoshi Tanaka, Hideki Fujimori, Yuki Togashi, Satoko Baba, Kengo Takeuchi, Kazuyoshi Katayanagi, Hiroshi Kurumaya, Hironori Kitade, Shinji Atagi, Seiji Yano

Author information

Yoshio Tsunezuka
Department of General Thoracic Surgery, Ishikawa Prefectural Central Hospital
Nobuyoshi Tanaka
Department of General Thoracic Surgery, Ishikawa Prefectural Central Hospital
Hideki Fujimori
Department of General Thoracic Surgery, Ishikawa Prefectural Central Hospital
Yuki Togashi
Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research
Satoko Baba
Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research
Kengo Takeuchi
Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research
Kazuyoshi Katayanagi
Department of Pathology, Ishikawa Prefectural Central Hospital
Hiroshi Kurumaya
Department of Pathology, Ishikawa Prefectural Central Hospital
Hironori Kitade
Chemotherapy Center, Houju Memorial Hospital
Shinji Atagi
Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center
Seiji Yano
Chemotherapy Center, Houju Memorial Hospital
Department of Medical Oncology, Kanazawa University Cancer Research Institute, Kanazawa University

Keywords: EGFR mutation, EML4-ALK, double cancers, alectinib

JOURNAL FREE ACCESS

2017 Volume 64 Issue 3.4 Pages 305-307

DOI https://doi.org/10.2152/jmi.64.305

Details

Abstract

A 36-year-old male was found two nodules in the right lower lobe of the lung. After the surgical resection, both lesions were diagnosed as invasive adenocarcinomas. One lesion was primarily lepidic growth component with EGFR-L858R mutation, and the other was micropapillary component with ALK translocation accompanying mediastinal lymphnode metastases. While he experienced disease recurrence, the disease was controlled by an ALK inhibitor, given based on the findings of surgical specimens. This is the first case who had two simultaneous lung cancers with EGFR mutation and ALK translocation in each respective lesion, and was successfully treated with ALK inhibitor at the post-surgical recurrence. J. Med. Invest. 64: 305-307, August, 2017

Corresponding author

Register with J-STAGE for free!